These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 25807773)
1. [Markers for non-invasive molecular genetic diagnosis of oncourological diseases]. Mikhaĭlenko DS; Perepechin DV; Apolikhin OI; Efremov GD; Sivkov AV Urologiia; 2014; (5):116-20. PubMed ID: 25807773 [TBL] [Abstract][Full Text] [Related]
2. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214 [TBL] [Abstract][Full Text] [Related]
3. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. Salagierski M; Schalken JA J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323 [TBL] [Abstract][Full Text] [Related]
4. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165 [TBL] [Abstract][Full Text] [Related]
5. Progensa™ PCA3 test for prostate cancer. Durand X; Moutereau S; Xylinas E; de la Taille A Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964 [TBL] [Abstract][Full Text] [Related]
6. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. Phé V; Cussenot O; Rouprêt M BJU Int; 2009 Oct; 104(7):896-901. PubMed ID: 19522860 [TBL] [Abstract][Full Text] [Related]
7. The study of DNA methylation in urological cancer: present and future. Andrés G; Ashour N; Sánchez-Chapado M; Ropero S; Angulo JC Actas Urol Esp; 2013 Jun; 37(6):368-75. PubMed ID: 23643196 [TBL] [Abstract][Full Text] [Related]
8. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564 [TBL] [Abstract][Full Text] [Related]
9. A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. Nguyen PN; Violette P; Chan S; Tanguay S; Kassouf W; Aprikian A; Chen JZ Eur Urol; 2011 Mar; 59(3):407-14. PubMed ID: 21144642 [TBL] [Abstract][Full Text] [Related]
10. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322 [TBL] [Abstract][Full Text] [Related]
11. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682 [TBL] [Abstract][Full Text] [Related]
12. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A; BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330 [TBL] [Abstract][Full Text] [Related]
14. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Cao DL; Ye DW; Zhang HL; Zhu Y; Wang YX; Yao XD Prostate; 2011 May; 71(7):700-10. PubMed ID: 20957673 [TBL] [Abstract][Full Text] [Related]
16. Methylated genes as potential biomarkers in prostate cancer. Phé V; Cussenot O; Rouprêt M BJU Int; 2010 May; 105(10):1364-70. PubMed ID: 20067451 [TBL] [Abstract][Full Text] [Related]
17. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Payne SR; Serth J; Schostak M; Kamradt J; Strauss A; Thelen P; Model F; Day JK; Liebenberg V; Morotti A; Yamamura S; Lograsso J; Sledziewski A; Semjonow A Prostate; 2009 Sep; 69(12):1257-69. PubMed ID: 19459176 [TBL] [Abstract][Full Text] [Related]
18. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Tombal B; Andriole GL; de la Taille A; Gontero P; Haese A; Remzi M; Speakman M; Smets L; Stoevelaar H Urology; 2013 May; 81(5):998-1004. PubMed ID: 23523291 [TBL] [Abstract][Full Text] [Related]
19. Urine markers in monitoring for prostate cancer. Jamaspishvili T; Kral M; Khomeriki I; Student V; Kolar Z; Bouchal J Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):12-9. PubMed ID: 19652665 [TBL] [Abstract][Full Text] [Related]
20. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. Rajput AB; Miller MA; De Luca A; Boyd N; Leung S; Hurtado-Coll A; Fazli L; Jones EC; Palmer JB; Gleave ME; Cox ME; Huntsman DG J Clin Pathol; 2007 Nov; 60(11):1238-43. PubMed ID: 17259299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]